Data from preclinical studies suggest that adding rituximab to an anti‐CD19 pyrrolobenzodiazepine ADC prolongs tumor control, providing a rationale for combining loncastuximab tesirine with rituximab as a treatment for R/R DLBCL.75 The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.